@article{e20a2984528b46f0aef14c1a1161af98,
title = "Platelet Function and Genotype after DES Implantation in East Asian Patients: Rationale and Characteristics of the PTRG-DES Consortium",
abstract = "Purpose: Platelet function test (PFT) results and genotype hold unique prognostic implications in East Asian patients. The aim of the PTRG-DES (Platelet function and genoType-Related long-term proGnosis in Drug-Eluting Stent-treated Patients with coronary artery disease) consortium is to assess the clinical impact thereof on long-term clinical outcomes in Korean patients with coronary artery disease during dual antiplatelet therapy (DAPT) including clopidogrel. Materials and Methods: Searching publications on the PubMed, we reviewed clopidogrel treatment studies with PFT and/or genotype data for potential inclusion in this study. Lead investigators were invited to share PFT/genotype results, patient characteristics, and clinical outcomes to evaluate relationships among them. Results: Nine registries from 32 academic centers participated in the PTRG-DES consortium, contributing individual patient data from 13160 patients who underwent DES implantation between July 2003 and August 2018. The PTRG-PFT cohort was composed of 11714 patients with available VerifyNow assay results. Platelet reactivity levels reached 218±79 P2Y12 reaction units (PRU), and high on-clopidogrel platelet reactivity based on a consensus-recommended cutoff (PRU >208) was observed in 55.9%. The PTRG-Genotype cohort consisted of 8163 patients with candidate genotypes related with clopidogrel responsiveness. Of those with cytochrome P450 (CYP) 2C19 genotype, frequencies of carrying one and two loss-of-function allele (s) (*2 or *3) were 47.9% (intermediate metabolizers) and 14.2% (poor metabolizers), respectively. Conclusion: The PTRG-DES consortium highlights unique values for on-clopidogrel platelet reactivity and CYP2C19 phenotype that may be important to developing optimal antiplatelet regimens in East Asian patients. Trial Registration: ClinicalTrials.gov Identifier: NCT04734028.",
keywords = "East Asia, coronary artery disease, drug-eluting stent, genotype, platelet function",
author = "{PTRG-DES Consortium Investigators} and Her, {Ae Young} and Jeong, {Young Hoon} and Kim, {Byeong Keuk} and Joo, {Hyung Joon} and Kiyuk Chang and Yongwhi Park and Song, {Young Bin} and Ahn, {Sung Gyun} and Suh, {Jung Won} and Lee, {Sang Yeup} and Cho, {Jung Rae} and Kim, {Hyo Soo} and Kim, {Moo Hyun} and Lim, {Do Sun} and Shin, {Eun Seok}",
note = "Funding Information: Received: November 16, 2021 Revised: December 31, 2021 Accepted: January 18, 2022 Corresponding author: Eun-Seok Shin, MD, PhD, Division of Cardiology, Ulsan University Hospital, University of Ulsan College of Medicine, 873 Bangeojinsunhwando-ro, Dong-gu, Ulsan 44033, Korea. Tel: 82-52-259-5425, Fax: 82-52-250-7058, E-mail: sesim1989@gmail.com *Ae-Young Her and Young-Hoon Jeong contributed equally to this work. •Dr. Jeong has received honoraria for lectures from AstraZeneca, Daiichi Sankyo, Sanofi-Aventis, Han-mi Pharmaceuticals, and Yuhan Pharmaceuticals, as well as research grants or support from Yuhan Pharmaceuticals and U&I Corporation. Dr. Song has received honoraria for lectures from AstraZeneca, Daiichi Sankyo, Sanofi-Aventis, Bayer Korea, and Samjin Pharmaceutical. Dr. Joo has received honoraria for lectures from AstraZeneca, Hanmi, Samjin, Dong-A, HK inno. N Pharmaceuticals, and DIO Medical Ltd. The other authors have no potential conflicts of interest to disclose. Funding Information: In total, nine prospective registries from 32 Korean academic centers have joined the PTRG-DES consortium, contributing data from 13160 DES patients treated between July 2003 and August 2018 in Supplementary Table 1 (only online). We obtained 11714 PFT results measured by the VerifyNow assay (PTRG-PFT cohort) and 8163 genotyping results related with clopidogrel responsiveness (PTRG-Genotype cohort) (Fig. 1). The type and number of patients in the PFT and/or genotyping datasets are provided in Supplementary Table 2 (only online). The PTRG-DES consortium is supported by the Platelet-Thrombosis Research Group under the Korean Society of Interventional Cardiology. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper and its final contents. The institutional review board of each participating center approved the registry and waived the requirement for written informed consent for access to institutional registries. The study was performed in accordance with the Good Clinical Practice Guidelines and the principles of the Declaration of Helsinki. Funding Information: The study was designed by the principal investigator and executive committee, and was sponsored by the Platelet-Thrombosis Research Group under the Korean Society of Intervention Cardiology. Publisher Copyright: {\textcopyright} Yonsei University College of Medicine 2022.",
year = "2022",
month = may,
doi = "10.3349/ymj.2022.63.5.413",
language = "English",
volume = "63",
pages = "413--421",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "5",
}